1-15 of 15
Lyndsay N. Harris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Mark H. O’Hara, Opeyemi Jegede, Mark A. Dickson, Angela M. DeMichele, Richard Piekarz, Robert J. Gray, Victoria Wang, Lisa M. McShane, Lawrence V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Adedayo Onitilo, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 56–64.
https://doi.org/10.1158/1078-0432.CCR-24-0036
Published: 06 January 2025
View article titled, Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Open the PDF for Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C in another window
Includes: Supplementary data
Journal Articles

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Roisin M. Connolly, Victoria Wang, David M. Hyman, Petros Grivas, Edith P. Mitchell, John J. Wright, Elad Sharon, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Jue Wang, Kari B. Wisinski, James V. Tricoli, Barbara A. Conley, Lyndsay N. Harris, Carlos L. Arteaga, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1273–1280.
https://doi.org/10.1158/1078-0432.CCR-23-0633
Published: 01 April 2024
View article titled, Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Open the PDF for Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal <em>HER2</em>-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J in another window
Includes: Supplementary data
Journal Articles

The New NCI Precision Medicine Trials

Lyndsay N. Harris, Charles D. Blanke, Harry P. Erba, James M. Ford, Robert J. Gray, Michael L. LeBlanc, Siwen Hu-Lieskovan, Mark R. Litzow, Selina M. Luger, Funda Meric-Bernstam, Peter J. O'Dwyer, Megan K.D. Othus, Katerina Politi, Lois E. Shepherd, Carmen J. Allegra, Helen X. Chen, S. Percy Ivy, Larissa A. Korde, Richard F. Little, Lisa M. McShane, Jeffrey A. Moscow, David R. Patton, Magdalena Thurin, Laura M. Yee, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4728–4732.
https://doi.org/10.1158/1078-0432.CCR-23-0917
Published: 01 December 2023
View article titled, The New NCI Precision Medicine Trials
Open the PDF for The New NCI Precision Medicine Trials in another window
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1477–1483.
https://doi.org/10.1158/1078-0432.CCR-22-2150
Published: 14 April 2023
View article titled, Phase II Study of Palbociclib (PD-0332991) in <em>CCND1</em>, <em>2</em>, or <em>3</em> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Open the PDF for Phase II Study of Palbociclib (PD-0332991) in <em>CCND1</em>, <em>2</em>, or <em>3</em> Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B in another window
Includes: Supplementary data
Journal Articles

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

Helen X. Chen, Minkyung Song, Holden T. Maecker, Sacha Gnjatic, David Patton, J. Jack Lee, Stacey J. Adam, Radim Moravec, Xiaole Shirley Liu, Ethan Cerami, James Lindsay, Ming Tang, F. Stephen Hodi, Catherine J. Wu, Ignacio I. Wistuba, Gheath Al-Atrash, Chantale Bernatchez, Sean C. Bendall, Stephen M. Hewitt, Elad Sharon, Howard Streicher, Rebecca A. Enos, Melissa D. Bowman, Valerie M. Tatard-Leitman, Beatriz Sanchez-Espiridion, Srinika Ranasinghe, Mina Pichavant, Diane M. Del Valle, Joyce Yu, Sylvie Janssens, Jenny Peterson-Klaus, Cathy Rowe, Gerold Bongers, Robert R. Jenq, Chia-Chi Chang, Jeffrey S. Abrams, Margaret Mooney, James H. Doroshow, Lyndsay N. Harris, Magdalena Thurin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (18): 5038–5048.
https://doi.org/10.1158/1078-0432.CCR-20-3241
Published: 15 September 2021
View article titled, Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)
Open the PDF for Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) in another window
Journal Articles

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, Funda Meric-Bernstam, Melissa S. Dillmon, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Andrew J. Aguirre, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 2996–3004.
https://doi.org/10.1158/1078-0432.CCR-21-0066
Published: 01 June 2021
View article titled, Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors
Open the PDF for Differential Outcomes in Codon 12/13 and Codon 61 <em>NRAS</em>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <em>NRAS</em>-Mutated Tumors in another window
Includes: Supplementary data
Journal Articles

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1812–1819.
https://doi.org/10.1158/1078-0432.CCR-19-3443
Published: 15 April 2020
View article titled, Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Open the PDF for Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131) in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Terry M. Hyslop, Brandelyn N. Pitcher, Matthew G. Soloway, Patricia A. Spears, Lynn N. Henry, Sara Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay N. Harris, Donald A. Berry, Elaine R. Mardis, Eric P. Winer, Clifford A. Hudis, Lisa A. Carey, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5292–5304.
https://doi.org/10.1158/1078-0432.CCR-17-3431
Published: 01 November 2018
View article titled, Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Challenge for Development of Valuable Immuno-oncology Biomarkers

Janice M. Mehnert, Arta M. Monjazeb, Johanna M.T. Beerthuijzen, Deborah Collyar, Larry Rubinstein, Lyndsay N. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 4970–4979.
https://doi.org/10.1158/1078-0432.CCR-16-3063
Published: 31 August 2017
View article titled, The Challenge for Development of Valuable Immuno-oncology Biomarkers
Open the PDF for The Challenge for Development of Valuable Immuno-oncology Biomarkers in another window
Journal Articles

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Vinay Varadan, Hannah Gilmore, Kristy L.S. Miskimen, David Tuck, Shikha Parsai, Amad Awadallah, Ian E. Krop, Eric P. Winer, Veerle Bossuyt, George Somlo, Maysa M. Abu-Khalaf, Mary Anne Fenton, William Sikov, Lyndsay N. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3249–3259.
https://doi.org/10.1158/1078-0432.CCR-15-2021
Published: 30 June 2016
View article titled, Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Open the PDF for Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, Kathleen Tenner, Karla Ballman, Robert B. Jenkins, Darren Riehle, Beiyun Chen, Ann E. McCullough, Nancy E. Davidson, Silvana Martino, George W. Sledge, Peter A. Kaufman, Leila A. Kutteh, Julie Gralow, Lyndsay N. Harris, James N. Ingle, Wilma L. Lingle, Edith A. Perez
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (20): 5798–5807.
https://doi.org/10.1158/1078-0432.CCR-13-0558
Published: 14 October 2013
View article titled, Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831
Open the PDF for Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2<sup>+</sup> Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 in another window
Includes: Supplementary data
Journal Articles

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Harold J. Burstein, Yu-Hui Chen, Leroy M. Parker, Jennifer Savoie, Jerry Younger, Irene Kuter, Paula D. Ryan, Judy E. Garber, Helen Chen, Susana M. Campos, Lawrence N. Shulman, Lyndsay N. Harris, Rebecca Gelman, Eric P. Winer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7871–7877.
https://doi.org/10.1158/1078-0432.CCR-08-0593
Published: 01 December 2008
View article titled, VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Open the PDF for VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy in another window
Journal Articles

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Lyndsay N. Harris, Fanglei You, Stuart J. Schnitt, Agnes Witkiewicz, Xin Lu, Dennis Sgroi, Paula D. Ryan, Steven E. Come, Harold J. Burstein, Beth-Ann Lesnikoski, Madhavi Kamma, Paula N. Friedman, Rebecca Gelman, J. Dirk Iglehart, Eric P. Winer
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1198–1207.
https://doi.org/10.1158/1078-0432.CCR-06-1304
Published: 22 February 2007
View article titled, Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Open the PDF for Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

Kimberly L. Blackwell, Mark W. Dewhirst, Vlayka Liotcheva, Stacey Snyder, Gloria Broadwater, Rex Bentley, Anita Lal, Gregory Riggins, Steve Anderson, Jim Vredenburgh, Alan Proia, Lyndsay N. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4083–4088.
https://doi.org/10.1158/1078-0432.CCR-03-0695
Published: 24 June 2004
View article titled, HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors
Open the PDF for HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors in another window